Skip to main content

A PHASE II RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF LETROZOLE WITH OR WITHOUT BYL719 OR BUPARLISIB, FOR THE NEOADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE BREAST CANCER

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

September 16, 2013

End Date

December 31, 2017
 

Administered By

Duke Cancer Institute

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

September 16, 2013

End Date

December 31, 2017